◎ Sugi Atlas

Atlas / Drug / Nadolol

Nadolol

drug
On this page

Also known as CorgardNadolol component of corzideNSC-758430SolgolSQ 11725SQ-11725SID56463045SID855594SID56422422SID144204197SID170464945C0165015

Summary

Nadolol (CHEMBL521606) is an approved small molecule (ATC C07AA12) targeting ADRB1, ADRB2, and ADRB3; indicated across 8 conditions including cardiovascular disorder and hypertensive disorder.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: C07AA12
  • Targets: 3 (ADRB1, ADRB2, ADRB3)
  • Indications: 8 conditions
  • Clinical trials: 13
  • Chemistry: 309.4 Da · C17H27NO4

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL521606
NameNadolol
TypeSmall molecule
Max phase4
FDA approvedno
PubChem CID4411
ATCC07AA12
Molecular formulaC17H27NO4
Molecular weight309.4
InChIKeyVWPOSFSPZNDTMJ-UHFFFAOYSA-N

SMILES: CC(C)(C)NCC(COC1=CC=CC2=C1CC(C(C2)O)O)O

IUPAC name: 5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol

Also known as: Corgard, Nadolol, Nadolol component of corzide, NSC-758430, Solgol, SQ 11725, SQ-11725, nadolol, SID56463045, SID855594, NADOLOL, SID56422422

Patent coverage: 38 distinct patent families (74 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
ADRB1β1-adrenoceptorAntagonist6.90%P08588
ADRB2β2-adrenoceptorAntagonist8.60.4%P07550
ADRB3β3-adrenoceptorAntagonist6.30.1%P13945

Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: ATP-dependent DNA helicase Q1, Beta-2 adrenergic receptor, Beta-1 adrenergic receptor, Alpha-1A adrenergic receptor.

Bioactivity

ChEMBL activities: 6 potent at pChembl ≥ 5 of 6 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
ADRB28.89Kd1.3nMCHEMBL_ACT_19403979
ADRB27.75AC5018nMCHEMBL_ACT_25123283
ADRB27.16Kd70nMCHEMBL_ACT_19403968
ADRB16.99AC50102nMCHEMBL_ACT_25122274
RECQL6.9Potency125.9nMCHEMBL_ACT_3674560
ADRA1A5.11AC507700nMCHEMBL_ACT_25218439

Target pathways

Aggregated over 3 target gene(s): ADRB1, ADRB2, ADRB3.

Top Reactome pathways

16 total, by targets touching each:

PathwayTargetsGenes
Signal Transduction3ADRB1, ADRB2, ADRB3
Signaling by GPCR3ADRB1, ADRB2, ADRB3
Class A/1 (Rhodopsin-like receptors)3ADRB1, ADRB2, ADRB3
Amine ligand-binding receptors3ADRB1, ADRB2, ADRB3
GPCR downstream signalling3ADRB1, ADRB2, ADRB3
Adrenoceptors3ADRB1, ADRB2, ADRB3
G alpha (s) signalling events3ADRB1, ADRB2, ADRB3
GPCR ligand binding3ADRB1, ADRB2, ADRB3
Membrane Trafficking1ADRB2
Metabolism of proteins1ADRB2
Vesicle-mediated transport1ADRB2
Deubiquitination1ADRB2
Ub-specific processing proteases1ADRB2
Post-translational protein modification1ADRB2
Cargo recognition for clathrin-mediated endocytosis1ADRB2
Clathrin-mediated endocytosis1ADRB2

Dominant GO biological processes

GO termTargets
diet induced thermogenesis3
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure3
adenylate cyclase-activating G protein-coupled receptor signaling pathway3
response to cold3
heat generation3
negative regulation of multicellular organism growth3
positive regulation of MAPK cascade3
brown fat cell differentiation3
adenylate cyclase-activating adrenergic receptor signaling pathway3
positive regulation of cold-induced thermogenesis3
signal transduction3
G protein-coupled receptor signaling pathway3
positive regulation of cardiac muscle cell apoptotic process2
adenylate cyclase-modulating G protein-coupled receptor signaling pathway2
negative regulation of smooth muscle contraction2

Indications & clinical

Indications

8 indications (5 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
cardiovascular disorder4MONDO:0004995EFO:0000319
hypertensive disorder4MONDO:0005044EFO:0000537
myocardial infarction4MONDO:0005068EFO:0000612
stroke disorder4MONDO:0005098EFO:0000712
hemangioma3MONDO:0006500EFO:1000635
asthma2MONDO:0004979MONDO:0004979

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 13.

Phase distribution

PhaseTrials
PHASE44
PHASE23
PHASE13
PHASE31
PHASE1/PHASE21
EARLY_PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00450164PHASE4COMPLETEDSecondary Prophylaxis After Variceal Bleeding in Non-Responders
NCT00567216PHASE4UNKNOWNEndoscopic Cyanoacrylate Obliteration vs. Nadolol Treatment in the Prevention of Gastric Variceal Rebleeding
NCT00921349PHASE4COMPLETEDA Trial of Ligation Plus Nadolol Versus Nadolol Alone in the Prophylaxis of First Variceal Bleeding in Cirrhosis
NCT01103154PHASE4COMPLETEDA Trial of Nadolol Plus Isosorbide Mononitrate Versus Carvedilol for the Prevention of Variceal Rebleeding
NCT02505971PHASE3COMPLETEDNadolol Versus Propranolol in Children With Infantile Hemangiomas
NCT00670267PHASE1/PHASE2COMPLETEDOral Nadolol for the Treatment of Adults With Mild Asthma
NCT01010308PHASE2COMPLETEDNadolol for Proliferating Infantile Hemangiomas
NCT01804218PHASE2UNKNOWNEfficacy and Safety of Beta-adrenoceptor Inverse Agonist, Nadolol, in Mild Asthma
NCT01825122PHASE2COMPLETEDEfficacy and Safety of Βeta-adrenoceptor Inverse Agonist and Biased Ligand, Nadolol, In Smoking Cessation of Patients With Chronic Cough With or Without Airflow Obstruction
NCT00647660PHASE1COMPLETEDFasting Study of Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg and Corzide® Tablets 80 mg/5 mg
NCT00648297PHASE1COMPLETEDFed Study of Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg and Corzide® Tablets 80 mg/5 mg
NCT00960245PHASE1COMPLETEDRelative Bioavailability Study of Nadolol (1 x 80 mg) Tablets Under Fasting Conditions
NCT06643221EARLY_PHASE1RECRUITINGExercise as an Immune Adjuvant for Allogeneic Cell Therapies

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

280 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
CrizotinibChEMBL + PubChemPhase 4 (approved)ADRB1, ADRB2, ADRB3
DesloratadineChEMBL + PubChemPhase 4 (approved)ADRB1, ADRB2, ADRB3
DihydroergotamineChEMBL + PubChemPhase 4 (approved)ADRB1, ADRB2, ADRB3
PramipexoleChEMBL + PubChemPhase 4 (approved)ADRB1, ADRB2, ADRB3
RIFAMPINChEMBL + PubChemPhase 4 (approved)ADRB1, ADRB2, ADRB3
TEGASERODChEMBL + PubChemPhase 4 (approved)ADRB1, ADRB2, ADRB3
ARIPIPRAZOLEChEMBLPhase 4 (approved)ADRB1, ADRB2, ADRB3
BISOPROLOLChEMBLPhase 4 (approved)ADRB1, ADRB2, ADRB3
BROMOCRIPTINEChEMBLPhase 4 (approved)ADRB1, ADRB2, ADRB3
CARVEDILOLChEMBLPhase 4 (approved)ADRB1, ADRB2, ADRB3
CLOTRIMAZOLEChEMBLPhase 4 (approved)ADRB1, ADRB2, ADRB3
EPINEPHRINEChEMBLPhase 4 (approved)ADRB1, ADRB2, ADRB3
FENOTEROLChEMBLPhase 4 (approved)ADRB1, ADRB2, ADRB3
FORMOTEROLChEMBLPhase 4 (approved)ADRB1, ADRB2, ADRB3
ISOPROTERENOLChEMBLPhase 4 (approved)ADRB1, ADRB2, ADRB3
LABETALOLChEMBLPhase 4 (approved)ADRB1, ADRB2, ADRB3
LEVOBUNOLOLChEMBLPhase 4 (approved)ADRB1, ADRB2, ADRB3
MONTELUKASTChEMBLPhase 4 (approved)ADRB1, ADRB2, ADRB3
NOREPINEPHRINEChEMBLPhase 4 (approved)ADRB1, ADRB2, ADRB3
PHENYLEPHRINEChEMBLPhase 4 (approved)ADRB1, ADRB2, ADRB3
PIMOZIDEChEMBLPhase 4 (approved)ADRB1, ADRB2, ADRB3
PINDOLOLChEMBLPhase 4 (approved)ADRB1, ADRB2, ADRB3
PRACTOLOLChEMBLPhase 4 (approved)ADRB1, ADRB2, ADRB3
PROPAFENONEChEMBLPhase 4 (approved)ADRB1, ADRB2, ADRB3
PROPRANOLOLChEMBLPhase 4 (approved)ADRB1, ADRB2, ADRB3
SALMETEROLChEMBLPhase 4 (approved)ADRB1, ADRB2, ADRB3
SOTALOLChEMBLPhase 4 (approved)ADRB1, ADRB2, ADRB3
TAMOXIFENChEMBLPhase 4 (approved)ADRB1, ADRB2, ADRB3
THIORIDAZINEChEMBLPhase 4 (approved)ADRB1, ADRB2, ADRB3
TIMOLOLChEMBLPhase 4 (approved)ADRB1, ADRB2, ADRB3
ALPRENOLOLChEMBLPhase 2ADRB1, ADRB2, ADRB3
BOPINDOLOLChEMBLPhase 2ADRB1, ADRB2, ADRB3
CIMATEROLChEMBLPhase 2ADRB1, ADRB2, ADRB3
FLESTOLOLChEMBLPhase 2ADRB1, ADRB2, ADRB3
LEVISOPRENALINEChEMBLPhase 2ADRB1, ADRB2, ADRB3
LEVOPROPRANOLOLChEMBLPhase 2ADRB1, ADRB2, ADRB3
MILVETEROLChEMBLPhase 2ADRB1, ADRB2, ADRB3
RAFABEGRONChEMBLPhase 2ADRB1, ADRB2, ADRB3
SOLABEGRONChEMBLPhase 2ADRB1, ADRB2, ADRB3
TRETOQUINOLChEMBLPhase 2ADRB1, ADRB2, ADRB3
XAMOTEROLChEMBLPhase 2ADRB1, ADRB2, ADRB3
ZENIDOLOLChEMBLPhase 2ADRB1, ADRB2, ADRB3
AlogliptinPubChemApprovedADRB1, ADRB2, ADRB3
BosentanPubChemApprovedADRB1, ADRB2, ADRB3
FidaxomicinPubChemApprovedADRB1, ADRB2, ADRB3
GlycopyrrolatePubChemApprovedADRB1, ADRB2, ADRB3
LinagliptinPubChemApprovedADRB1, ADRB2, ADRB3
MethotrexatePubChemApprovedADRB1, ADRB2, ADRB3
PropoxyphenePubChemApprovedADRB1, ADRB2, ADRB3
PyrazinamidePubChemApprovedADRB1, ADRB2, ADRB3
Tiotropium Bromide MonohydratePubChemApprovedADRB1, ADRB2, ADRB3
CLOZAPINEChEMBL + PubChemPhase 4 (approved)ADRB2, ADRB3
OLANZAPINEChEMBL + PubChemPhase 4 (approved)ADRB2, ADRB3
OLODATEROLChEMBL + PubChemPhase 4 (approved)ADRB1, ADRB2
TAMSULOSINChEMBL + PubChemPhase 4 (approved)ADRB1, ADRB2
ACEBUTOLOLChEMBLPhase 4 (approved)ADRB1, ADRB2
ALBUTEROLChEMBLPhase 4 (approved)ADRB1, ADRB2
AMIODARONEChEMBLPhase 4 (approved)ADRB1, ADRB3
AMITRIPTYLINEChEMBLPhase 4 (approved)ADRB1, ADRB2
AMLODIPINEChEMBLPhase 4 (approved)ADRB2, ADRB3

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot